Gilead Sciences Inc. has acquired Interius BioTherapeutics for $350 million in cash to advance next-gen cell therapy. The acquisition will integrate Interius’s in vivo platform into Kite’s existing cell therapy framework, aiming to develop a new approach to CAR T-cell therapy generating cells inside the patient’s body.

This move builds upon Gilead’s two FDA-approved CAR T-cell therapies, Yescarta and Tecartus, for certain blood cancers. Interius, spun out of the University of Pennsylvania, was the first biotech to advance an in vivo CAR T-cell therapy into a clinical trial. Gilead Sciences Inc. is a biopharmaceutical company that operates globally.

While Gilead shows investment potential, some AI stocks may offer greater upside with less downside risk. For those seeking an undervalued AI stock that could benefit from Trump-era tariffs and onshoring trends, consider exploring the best short-term AI stock. For more insights, read about 30 stocks that could double in 3 years and 11 hidden AI stocks to buy now. This article was originally published on Insider Monkey’s website.

Read more at Yahoo Finance: Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy